PRGO
$10.30
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
Intraday
Recent News
Canaccord’s Susan Anderson Trims Perrigo (PRGO) Target but Notes Share Gains in Core Business
Perrigo Company plc (NYSE:PRGO) is included among the 13 Extreme Dividend Stocks with Huge Upside Potential. On February 27, Canaccord analyst Susan Anderson lowered the firm’s price recommendation on Perrigo Company plc (NYSE:PRGO) to $17 from $20. It reiterated a Buy rating on the shares. The firm said management noted that the company finished Q4 […]
Risk-Savvy Investors Love 4 Passive Income Kings Yielding 10% and More
Investors love ultra-high-yield dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time. In other words, the total return on an investment or portfolio consists of income and stock appreciation. At 24/7 Wall St., we have ... Risk-Savvy Investors Love 4 Passive Income Kings Yielding 10% and More
Perrigo (PRGO) Is Down 18.9% After Deepening Net Loss and Weak 2026 Outlook - What's Changed
Perrigo Company plc recently reported its fourth quarter and full-year 2025 results, posting full-year sales of US$4.25 billion, a much larger net loss of US$1.43 billion, and a wider loss per share compared with the prior year. Alongside these results, Perrigo issued a 2026 outlook calling for a 1.5%–5.5% sales decline, signaling ongoing business pressures at a time when investors had been focused on a potential earnings recovery. We’ll now examine how Perrigo’s sharp increase in full-year...
Perrigo Q4 Earnings Call Highlights
Perrigo (NYSE:PRGO) executives outlined “meaningful progress” in 2025 while acknowledging a softer consumer health market and continued challenges in infant formula, according to the company’s fourth-quarter and full-year 2025 earnings call held Thursday. CEO Patrick Lockwood-Taylor said the compan
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Perrigo misses Q4 EPS estimates. Its 2026 sales and profit estimates are below expectations as Infant Formula headwinds persist. Shares slide on weak guidance.